The Androgenic Alopecia drugs in development market research report provides comprehensive information on the therapeutics under development for Androgenic Alopecia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Androgenic Alopecia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Androgenic Alopecia and features dormant and discontinued products.
GlobalData tracks 49 drugs in development for Androgenic Alopecia by 39 companies/universities/institutes. The top development phase for Androgenic Alopecia is preclinical with 15 drugs in that stage. The Androgenic Alopecia pipeline has 48 drugs in development by companies and one by universities/ institutes. Some of the companies in the Androgenic Alopecia pipeline products market are: Epibiotech, Amplifica Holdings Group and Cutia Therapeutics.
The key targets in the Androgenic Alopecia pipeline products market include Androgen Receptor, 3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2, and Prostaglandin F2 Alpha.
The key mechanisms of action in the Androgenic Alopecia pipeline product include 3-Oxo 5-Alpha Steroid 4 Dehydrogenase 2 Inhibitor with six drugs in Pre-Registration. The Androgenic Alopecia pipeline products include seven routes of administration with the top ROA being Topical and eight key molecule types in the Androgenic Alopecia pipeline products market including Small Molecule, and Cell Therapy.
Androgenic Alopecia overview
Androgenic alopecia, commonly known as male-pattern baldness or female-pattern hair loss, is a hereditary condition that leads to gradual hair thinning and eventual hair loss in a specific pattern. It is the most common type of hair loss and affects both men and women, although the presentation and progression may differ between the sexes. Androgenic alopecia is primarily influenced by genetic and hormonal factors. It is associated with the hormone dihydrotestosterone (DHT), a derivative of testosterone, which can affect hair follicles by causing them to shrink or miniaturize over time. This results in shorter and thinner hair growth cycles, leading to eventual hair loss. The primary symptom of androgenic alopecia is a gradual reduction in hair volume and thickness in the affected areas. Hair may become finer, shorter, and less dense, ultimately leading to visible scalp exposure.
For a complete picture of Androgenic Alopecia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
